NCT03376997

Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

An Open-Label, Randomized, Crossover Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Eisai Inc. · Industry
• Sex: All
• Age: 20 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study will be conducted to evaluate the bioavailability of a single 12 milligram (mg) dose of perampanel intravenous infusions of different durations relative to a single 12 mg dose of perampanel oral tablet in healthy participants.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	Perampanel	IV infusion
DRUG	Perampanel	Oral tablet

Timeline

• Start date: 2017-11-08
• Primary completion: 2018-02-16
• Completion: 2018-02-16
• First posted: 2017-12-19
• Last updated: 2018-09-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study